Skip to main content
. 2022 Sep;10(18):1026. doi: 10.21037/atm-22-3746

Figure 4.

Figure 4

Changes in CT images of metastases from January 11, 2021 to May 06, 2022. According to the RECIST 1.1 criteria, after 40 days of avapritinib combined with sunitinib therapy for the 6 target lesions, including 3 peritoneal metastases and 3 liver metastases, with the exception of the hepatic S8 metastasis that was slightly larger than before, the other metastatic lesions were all reduced and the mass beside the head of the pancreas was reduced by about 23% compared to the previous measurement taken on January 11, 2022; The CT scan after 4 months of avapritinib combined with sunitinib therapy indicated that all the lesions were still responsive, the main lesion was continuously shrinking. The imaging results of the lesions: (A) The tumor beside the head of the pancreas. (B) Peritoneal lesion 1. (C) Peritoneal lesion 2. (D) Hepatic S4 metastasis; (E) hepatic S8 metastasis; (F) hepatic S5 metastasis. CT, computed tomography.